GlassScriptPhysician profile
Karen Haiber
NPI 1720519127
$3,711.09
in general payments reported to CMS, 2019-2025
27 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $221 · 2021: $938 · 2022: $975 · 2023: $1,323 · 2024: $116 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.37 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $632.37 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $445.87 | 2020-2023 | Rylaze |
| Merck Sharp & Dohme LLC | $352.89 | 2022-2023 | Keytruda |
| Incyte Corporation | $282.33 | 2020-2023 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $263.12 | 2021-2023 | Tagrisso |
| Abbvie INC. | $220.21 | 2020-2023 | |
| Celgene Corporation | $201.25 | 2021-2023 | Reblozyl |
| Amgen INC. | $199.16 | 2020-2023 | Kyprolis |
| Astellas Pharma US INC | $168.96 | 2022-2023 | Padcev |
| Gilead Sciences, INC. | $137.42 | 2025 | Trodelvy |
| Mirati Therapeutics, INC. | $134.28 | 2023-2024 | Krazati |
| Apellis Pharmaceuticals, INC. | $129.50 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.73 | 2023 | |
| Servier Pharmaceuticals LLC | $67.69 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $58.09 | 2022-2023 | Somatuline Depot, Onivyde |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $46.36 | 2020-2022 | |
| Eisai INC. | $36.43 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $31.98 | 2022 | |
| Puma Biotechnology, INC. | $28.98 | 2023 | |
| Janssen Biotech, INC. | $26.97 | 2024 | Tecvayli |
| Blueprint Medicines Corporation | $26.90 | 2023 | Ayvakit |
| Epizyme, INC. | $24.53 | 2020 | |
| Adc Therapeutics America, INC. | $24.20 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.53 | 2023 | Givlaari |
| Lilly USA, LLC | $18.37 | 2022 | |
| Deciphera Pharmaceuticals INC. | $16.96 | 2023 | Qinlock |
| Glaxosmithkline, LLC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Haiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.